NRx Pharmaceuticals, Inc.
NRXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $5 | $5 | $4 | $2 |
| Gross Profit | -$5 | -$5 | -$4 | -$2 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,199 | $13,371 | $17,027 | $20,257 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $13,500 | $14,211 | $27,304 | $74,942 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19,699 | $27,582 | $44,331 | $95,199 |
| Operating Income | -$19,704 | -$27,587 | -$44,335 | -$95,201 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$5,422 | -$2,563 | $4,581 | $2,138 |
| Pre-Tax Income | -$25,126 | -$30,150 | -$39,754 | -$93,063 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25,126 | -$30,150 | -$39,754 | -$93,063 |
| % Margin | – | – | – | – |
| EPS | -2.39 | -3.98 | -0.6 | -7.44 |
| % Growth | 39.9% | -563.3% | 91.9% | – |
| EPS Diluted | -2.39 | -3.98 | -0.6 | -7.44 |
| Weighted Avg Shares Out | 10,517 | 7,576 | 65,767 | 46,918 |
| Weighted Avg Shares Out Dil | 10,517 | 7,576 | 65,767 | 46,918 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44 | $494 | $249 | $0 |
| Interest Expense | $1,079 | $120 | $0 | $18 |
| Depreciation & Amortization | $5 | $5 | $4 | $2 |
| EBITDA | -$24,042 | -$30,025 | -$39,750 | -$93,043 |
| % Margin | – | – | – | – |